# Texas Votes Big for Alzheimer's Research Boost!

Newsy: Alzheimer’s News Weekly
Published: 2025-11-10T14:30:00.334Z
Source: https://newsyai.com/edition/8ddf382e-4fc8-4991-bb3e-cdfcad517047
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# The Alzheimer’s Treatment Briefing
Coverage period: November 4–10, 2025 (U.S.)

Note up front: It was a light week for new trial readouts or approvals. Still, two developments add meaningful, practical signal for treatment access and near‑term care decisions.

## Top stories (ranked)

1) Texas voters approve $3B dementia research and treatment initiative
- What’s new
  - On November 5, Texans passed Proposition 14 to create the Dementia Prevention and Research Institute of Texas (DPRIT) with $3 billion over 10 years (up to $300M per year). It’s modeled on the state’s successful cancer research fund and is described as the largest state‑funded dementia effort in the U.S. ([alz.org](https://www.alz.org/news/2025/texas-proposition-14-passes-nations-largest-state-funded-dementia-research-initiative?utm_source=openai))
- Why this matters
  - This scale of funding can accelerate promising treatments (drug and non‑drug), attract trial sites and specialists to Texas, and shorten wait times for patients by expanding clinical capacity. Expect more prevention and early‑treatment studies, and more options for Texans to join trials without traveling out of state. ([houstonchronicle.com](https://www.houstonchronicle.com/health/article/texas-dementia-alzheimers-research-funding-21124632.php?utm_source=openai))

2) Real‑world lecanemab experience: practical safety and persistence data from a tertiary center
- What’s new
  - A newly indexed real‑world report describes how an academic program screened 169 people and started 86 on lecanemab, tracking cognition, safety events, and reasons for stopping. About 19.8% discontinued (side effects, comorbidities, costs, preference). Amyloid‑related MRI changes (ARIA) occurred in 18.6%, mostly without symptoms; one symptomatic ARIA led to hospitalization and stopping treatment. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40437535/?utm_source=openai))
- Why this matters
  - These “on‑the‑ground” numbers help clinics and families plan: set expectations about MRI monitoring, budget and logistics, and who is most likely to continue therapy. They also reinforce the need for clear counseling on ARIA and for systems that minimize drop‑offs unrelated to medical reasons. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40437535/?utm_source=openai))

3) New AI tool aims to speed triage for treatment by combining tests and scans
- What’s new
  - A preprint (Nov 4) introduces BRAINS, an AI system that merges cognitive scores and brain imaging to classify disease stage and flag early decline. While not a treatment, faster and more accurate triage can route the right patients to disease‑slowing therapies and trials sooner. ([arxiv.org](https://arxiv.org/abs/2511.02490?utm_source=openai))
- Why this matters
  - Access to antibodies and upcoming therapies depends on finding eligible patients early and tracking them reliably. If validated clinically, tools like this could reduce delays to treatment starts and help clinics manage growing caseloads. ([arxiv.org](https://arxiv.org/abs/2511.02490?utm_source=openai))

## What this means in plain language
- Texas’ new institute should translate into more nearby trials, more specialists, and potentially faster access to cutting‑edge treatments—especially for people who can’t travel far. Watch for new study openings in 2026. ([alz.org](https://www.alz.org/news/2025/texas-proposition-14-passes-nations-largest-state-funded-dementia-research-initiative?utm_source=openai))
- Real‑world lecanemab use continues to show that most MRI side effects are mild, but careful monitoring and upfront planning (appointments, costs, transportation) are essential to keep people on therapy. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40437535/?utm_source=openai))
- Smarter screening tools won’t replace doctors, but they can help clinics find eligible patients earlier—which matters because current disease‑slowing drugs work best at the earliest stages. ([arxiv.org](https://arxiv.org/abs/2511.02490?utm_source=openai))

## Quick guidance for patients and caregivers this week
- If you’re in Texas, ask local centers whether DPRIT funding could open nearby trials or expand infusion/MRI capacity in 2026. ([alz.org](https://www.alz.org/news/2025/texas-proposition-14-passes-nations-largest-state-funded-dementia-research-initiative?utm_source=openai))
- Starting or considering lecanemab? Discuss your site’s ARIA plan (MRI timing, symptom checks) and practical supports to reduce non‑medical discontinuation (transport, scheduling, insurance). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40437535/?utm_source=openai))
- Ask clinics about tools they use to speed diagnosis and eligibility checks; earlier confirmation can mean earlier access to disease‑slowing treatment. ([arxiv.org](https://arxiv.org/abs/2511.02490?utm_source=openai))

If you want, I can track late‑breaking treatment data as it lands in early December and deliver a same‑day, plain‑English digest focused strictly on what changes for care.
